(R)-1-(1-methyl-5-phenyl-1H-pyrazol-3-yl)-ethylamine | 1007881-39-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (R)-1-(1-methyl-5-phenyl-1H-pyrazol-3-yl)-ethylamine
• 英文别名: (1R)-1-(1-methyl-5-phenylpyrazol-3-yl)ethanamine
• CAS: 1007881-39-1
• 化学式: C₁₂H₁₅N₃
• 分子量: 201.271
• InChiKey: RDHMDPDGOAILPF-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] NOVEL CALCIUM SENSING RECEPTOR MODULATING COMPOUNDS AND PHARMACEUTICAL USE THEREOF<br/>[FR] NOUVEAUX COMPOSÉS MODULANT LE RÉCEPTEUR SENSIBLE AU CALCIUM, ET LEUR UTILISATION PHARMACEUTIQUE
  申请人：LEO PHARMA AS

  公开号：WO2010136037A1

  公开（公告）日：2010-12-02

  The invention relates to novel calcium-sensing receptor (CaSR) modulating substituted cyclopentylene compounds represented in formula I and derivatives thereof, to said compounds for use as a medicament, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds, and to the use of said compounds in the manufacture of medicaments.

  该发明涉及一种表示为公式I的新型调节钙感受受体（CaSR）的取代环戊烯化合物及其衍生物，该化合物用作药物，用于治疗的化合物，包含该化合物的制药组合物，使用该化合物治疗疾病的方法以及使用该化合物制造药物。
• SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES
  申请人：Liang Xifu

  公开号：US20100279936A1

  公开（公告）日：2010-11-04

  The invention relates to novel compounds according to formula Ia and Ib; (Formula Ia and Ib) wherein A represents substituted or unsubstituted C 1-10 heteroaryl, C 6-14 aryl or C 6-10 heterocycloalkylaryl; R 1 is C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 hydroxyalkyl, C 1-6 haloalkyl, C 1-6 amino, C 3-6 cycloalkyl, or C 1-6 heterocycloalkyl, each of which are optionally substituted; X represents —CR 3 R 4 —(CR 5 R 6 ) n —(CR 7 ═CR 8 ) m —(C 6-14 aryl) r -(C 1-10 heteroaryl) s -(CR 9 R 10 ) p —(CR 11 ═CR 12 ) q , R 2 represents C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 hydroxyalkyl, C 1-6 haloalkyl, C 1-6 amino, C 1-12 alkylsilyl, C 6-30 alkylarylsilyl, C 1-10 heteroaryl, C 6-14 aryl, C 1-10 heterocycloalkyl, C 1-10 heterocycloalkenyl, C 1-8 cycloalkyl, C 1-18 cycloalkenyl, each of which is optionally substituted, or R 2 represents hydrogen, carboxy, or hydroxy; or a pharmaceutically acceptable salt, solvate, or ester thereof; to processes for the preparation thereof, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, wherein said compounds being useful, e.g. in the treatment of diseases associated with disturbances of CaSR activity, such as hyperparathyroidism.

  该发明涉及新型化合物，其符合公式Ia和Ib;（公式Ia和Ib）其中A代表取代或未取代的C1-10杂环芳基，C6-14芳基或C6-10杂环烷基芳基; R1为C1-6烷基，C2-6烯基，C2-6炔基，C1-6羟基烷基，C1-6卤代烷基，C1-6氨基，C3-6环烷基或C1-6杂环烷基，每个基团都可以取代; X代表—CR3R4—（CR5R6）n—（CR7═CR8）m—（C6-14芳基）r-（C1-10杂环芳基）s-（CR9R10）p—（CR11═CR12）q，R2代表C1-6烷基，C2-6烯基，C2-6炔基，C1-6羟基烷基，C1-6卤代烷基，C1-6氨基，C1-12烷基硅烷基，C6-30烷基芳基硅烷基，C1-10杂环芳基，C6-14芳基，C1-10杂环烷基，C1-10杂环烯基，C1-8环烷基，C1-18环烯基，每个基团都可以取代，或R2代表氢，羧基或羟基;或其药学上可接受的盐，溶剂或酯;用于制备该化合物的工艺，以及用于治疗的化合物，包括该化合物的制药组合物，其中该化合物可用于治疗与CaSR活性紊乱有关的疾病，例如甲状旁腺功能亢进症。
• NOVEL CALCIUM SENSING RECEPTOR MODULATING COMPOUNDS AND PHARMACEUTICAL USE THEREOF
  申请人：Nørremark Bjarne

  公开号：US20120122784A1

  公开（公告）日：2012-05-17

  The invention relates to novel calcium-sensing receptor (CaSR) modulating substituted cyclopentylene compounds represented in formula I and derivatives thereof, to said compounds for use as a medicament, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds, and to the use of said compounds in the manufacture of medicaments.

  该发明涉及一种新型的钙感受受体（CaSR）调节代替环戊烯化合物，其在式I中表示及其衍生物，以及将该化合物用作药物的方法，将该化合物用于治疗的方法，包含该化合物的制药组合物，使用该化合物治疗疾病的方法，以及将该化合物用于制造药物的用途。
• US8765676B2
  申请人：——

  公开号：US8765676B2

  公开（公告）日：2014-07-01
• [EN] SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES<br/>[FR] COMPOSÉS ACÉTYLÉNIQUES SUBSTITUÉS UTILES POUR LE TRAITEMENT DE CERTAINES MALADIES
  申请人：LEO PHARMA AS

  公开号：WO2008019690A1

  公开（公告）日：2008-02-21

  [EN] The invention relates to novel compounds according to formula Ia and Ib; (Formula Ia and Ib) wherein A represents substituted or unsubstituted C_1-10heteroaryl, C_6-14aryl or C_{6- 10}heterocycloalkylaryl; R₁ is C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_1-6hydroxyalkyl, C_1-6haloalkyl, C_1-6amino, C_3-6 cycloalkyl, or C_1-6heterocycloalkyl, each of which are optionally substituted; X represents -CR₃R₄-(CR₅R₆)_n-(CR₇=CR₈)_m-(C_6-14aryl)_r-(C_1-10heteroaryl)_s-(CR₉R₁₀)_p- (CR₁₁ = CR₁₂)_q, R₂ represents C_1-6alkyl, C_2-6alkenyl, C_2-6alkynyl, C_1-6hydroxyalkyl, C_1-6haloalkyl, C_1-6amino, C_1-12alkylsilyl, C_6-30alkylarylsilyl, C_1-10heteroaryl, C_6-14aryl, C_1-10heterocycloalkyl, C_1-10heterocycloalkenyl, C_1-8cycloalkyl, C_1-18cycloalkenyl, each of which is optionally substituted, or R₂ represents hydrogen, carboxy, or hydroxy; or a pharmaceutically acceptable salt, solvate, or ester thereof; to processes for the preparation thereof, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, wherein said compounds being useful, e.g. in the treatment of diseases associated with disturbances of CaSR activity, such as hyperparathyroidism.
  [FR] L'invention concerne de nouveaux composés représentés par les formules Ia et Ib; (formule Ia et Ib) dans lesquelles A représente un groupe hétéroaryle en C_1-10 substitué ou non substitué, aryle en C_6-14 ou hétérocycloalkylaryle en C_6-10; R₁ est un groupe alkyle en C_1-6, alcényle en C_2-6, alcynyle en C_2-6, hydroxyalkyle en C_1-6, halogénoalkyle en C_1-6, amino en C_1-6; cycloalkyle en C_3-6 ou hétérocycloalkyle en C_1-6, chacun pouvant être éventuellement substitué; X représente -CR₃R₄-(CR₅R₆)_n-(CR₇=CR₈)_m-(aryle en C_6-14)_r-(hétéroaryle en C₁-C₁₀)_s-(CR₉R₁₀)_p-(CR₁₁=CR₁₂)_q, R₂ représente un groupe alkyle en C_1-6, alcényle en C_2-6, alcynyle en C_2-6, hydroxyalkyle en C_1-6, halogénoalkyle en C_1-6, amino en C_1-6, alkylsilyle en C_1-12, alkylarylsilyle en C_6-30, hétéroaryle en C_1-10, aryle en C_6-14, hétérocycloalkyle en C_1-10, hétérocycloalcényle en C_1-10, cycloalkyle en C_1-8, cycloalcényle en C_1-18, chacun pouvant être éventuellement substitué, ou R₂ représente de l'hydrogène, un groupe carboxy ou hydroxy; ou un sel acceptable du point de vue pharmaceutique, un solvant ou un ester de ceux-ci. L'invention concerne des processus pour la préparation des composés précités destinés à être utilisés en thérapie, des compositions pharmaceutiques comprenant les composés précités, les composés étant utiles par exemple dans le traitement de maladies associées aux perturbations de l'activité CaSR, comme l'hyperparathyroïdie.